재발 난소암에서 자음강화탕 투여를 통한 Liposomal Doxorubicin, Carboplatin병합요법 부작용 경감 효과 1례

키워드

참고문헌 (38)

1. "Incidence of 61 Cancers by Sex and 5-Year Age Groups" (2019)[URL]
2. Henderson JT, "Screening for Ovarian Cancer : Updated Evidence Report and Systematic Review for the US Preventive Services Task Force", JAMA, 319(6), pp.595~606 (2018)
3. Rossi L, "Bevacizumab in ovarian cancer : A critical review of phase III studies", Oncotarget, 8(7), pp.12389~12405 (2016)
4. Matulonis UA, "Ovarian cancer", Nat Rev Dis Primers, 2, pp.16061~ (2016)
5. Staropoli N, "Pegylated liposomal doxorubicin in the management of ovarian cancer : a systematic review and meta-analysis of randomized trials", Cancer Biol Ther, 15(6), pp.707~720 (2014)
6. Rafiyath SM, "Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis", Exp Hematol Oncol, 1(1), pp.10~ (2012)
7. McKeage MJ, "Comparative adverse effect profiles of platinum drugs", Drug Saf, 13(4), pp.228~244 (1995)
8. Chen D, "Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer : Progress and Perspective", Front Pharmacol, 9, pp.1442~ (2018)
9. Yamakawa J, "Role of Kampo medicine in integrative cancer therapy", Evid Based Complement Alternat Med, 2013, pp.570848~ (2013)
10. Yamakawa J, "Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients", Evid Based Complement Alternat Med, 2013, pp.746486~ (2013)
11. Chan KK, "The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer : a double-blind placebo-controlled randomized trial with immunological monitoring", Ann Oncol, 22(10), pp.2241~2249 (2011)
12. Wu YH, "Use of Chinese Herbal Medicine Improves Chemotherapy-Induced Thrombocytopenia among Gynecological Cancer Patients : An Observational Study", Evid Based Complement Alternat Med, 2018, pp.4201325~ (2018)
13. Wang R, "Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy : A Systematic Review and Meta-Analysis", Front Oncol, 9, pp.730~ (2019)
14. Kim KS, "Clinical Practice Guideline for Korean Medicine for Ovarian Cancer", J of Kor Traditional Oncologyl, 21(2), pp.37~50 (2016)
15. 정홍매, "자음강화탕 투여 후 상열감의 호전을 보인 타목시펜 복용 중인 유방암 환자 1례", 대한한방내과학회지, 31(2), pp.395~400 (2010), 대한한방내과학회
16. Wang Z, "An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics", Biosci Trends, 12(3), pp.220~239 (2018)
17. Qi F, "The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer", Biosci Trends, 9(1), pp.16~34 (2015)
18. Shankar A, "Current Trends in Management of Oral Mucositis in Cancer Treatment", Asian Pac J Cancer Prev, 18(8), pp.2019~2026 (2017)
19. Staff NP, "Chemotherapy-induced peripheral neuropathy : A current review", Ann Neurol, 81(6), pp.772~781 (2017)
20. Scully C, "Oral mucositis", Oral Dis, 12(3), pp.229~241 (2006)
21. Brewer JR, "Chemotherapy-induced peripheral neuropathy : Current status and progress", Gynecol Oncol, 140(1), pp.176~183 (2016)
22. Avan A, "Platinum-induced neurotoxicity and preventive strategies : past, present, and future", Oncologist, 20(4), pp.411~432 (2015)
23. Kuriyama A, "Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy : a systematic review and meta-analysis", Support Care Cancer, 26(4), pp.1051~1059 (2018)
24. Hoshino N, "Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy : a systematic review and meta-analysis", Int J Clin Oncol, 23(3), pp.434~442 (2018)
25. Nishikawa K, "The clinical impact of Hangeshashinto(TJ-14)in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer : Analyses of pooled data from two phase II randomized clinical trials(HANGESHA-G and HANGESHA-C)", J Cancer, 9(10), pp.1725~1730 (2018)
26. He DY, "Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall. a traditional chinese herbal medicine", Front Pharmacol, 2, pp.10~ (2011)
27. Chen XP, "Phytochemical and pharmacological studies on Radix Angelica sinensis", Chin J Nat Med, 11(6), pp.577~587 (2013)
28. Zhu B, "The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz : A review", J Ethnopharmacol, 226, pp.143~167 (2018)
29. Wang Y, "The genus Anemarrhena Bunge : A review on ethnopharmacology, phytochemistry and pharmacology", J Ethnopharmacol, 153(1), pp.42~60 (2014)
30. Guan F, "Majority of Chinese Medicine Herb Category"Qing Re Yao"Have Multiple Mechanisms of Anti-inflammatory Activity", Sci Rep, 8(1), pp.7416~ (2018)
31. Liu T, "NF-κB signaling in inflammation", Signal Transduct Target Ther, 2, pp.17023~ (2017)
32. Zhang Q, "30 Years of NF-κB:A Blossoming of Relevance to Human Pathobiology", Cell, 168(1-2), pp.37~57 (2017)
33. Wang C, "Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation-Induced Oral Mucositis in Patients Receiving Radiotherapy : A Randomized Controlled Trial", Integr Cancer Ther, 17(2), pp.444~450 (2017)
34. Cheng YY, "Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics", J Food Drug Anal, 26(2S), pp.S88~S95 (2018)
35. 정창운, "대만 건강보험청구데이터(NHIRD)를 이용한 전통 동아시아 의학(TEAM) 임상연구의 현황", 한방재활의학과학회지, 27(2), pp.67~75 (2017), 한방재활의학과학회
36. Lin FX, "Chinese medicine for outcomes in colorectal cancer patients : A retrospective clinical study", Chin J Integr Med, 23(9), pp.648~653 (2017)
37. Jiao L, "Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients", Sci Rep, 7, pp.46524~ (2017)
38. Ramos-Esquivel A, "Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer : A Prospective Study of Medication Surveillance", J Oncol Pract, 13(7), pp.613~622 (2017)

관련 논문AI추천